



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

November 9, 2022

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir/ Madam,

Sub: Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed intimation dated November 8, 2022, received from Link Intime India Private Limited, Registrar and Transfer Agent, providing information regarding issue of duplicate share certificates in favour of shareholders of the Company.

Further, in accordance with the SEBI Notification No. SEBI/LAD-NRO/GN/2022/66 dated January 24, 2022, read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, letter of confirmations in lieu of the physical share certificates will be issued to the said shareholders of the Company within the prescribed timelines.

Request you to take the same on record as required under the provisions of the said Regulation.

Thanking you,

Yours Sincerely,

For Novartis India Limited

Malpani Nikhil
Digitally signed by Malpani Nikhil
DN: dc=com, dc=novartis, ou=people, ou=GR,
serialNumber=3079258, cn=Malpani Nikhil
Date: 2022.11.09 17:43:35 +05'30'

Nikhil Malpani
Company Secretary and Compliance Officer

Date: 08.11.2022

To,
Company Secretary
Novartis India Limited

Sub: Regulation 39(3) of SEBI (LODR), 2015.

Dear Sir / Madam,

Please find below mentioned details pertaining to the security for which Duplicate Certificates has been issued considering approval date 08.11.2022

Sl. No.	Shareholder(s) Name	Folio No.	New Certificate No.	No. of Shares	Distinctive nos.
1	ANJANA AGARWAL	03093998	442003	20	26451-26470

Yours Faithfully,
Link Intime India Private Limited


Authorized Signatory